The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor ... meningococcal infections caused by Neisseria meningitidis that is on Soliris ...

a FcRN antagonist approved for gMG * rituximab * other approved gMG therapies excluding complement inhibitors. * Consistent with all other iptacopan trials, participants will have to be vaccinated ...

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have ...

This is caused by the bacteria Neisseria meningitidis. She says the bacteria got into his bloodstream, and he passed within a few days of symptoms. DHEC reports there have been 12 cases of ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.

was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11–55 years. The first meningococcal vaccine ...

Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks No new safety signals ...

It can be caused by viruses, bacteria, or fungi. Meningococcal meningitis occurs when the bacterium Neisseria meningitidis infects the meninges (tissues around the brain and spinal cord).